The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Kidney Outcomes in Long COVID
Open accessAbstract
Significance Statement: Patients who survive coronavirus disease 2019 (COVID-19) are at higher risk of post-acute sequelae involving pulmonary and several extrapulmonary organ systems—generally referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. Here we show that, beyond the acute phase of illness, 30-day survivors of COVID-19 exhibited higher risks of AKI, eGFR decline, ESKD, major adverse kidney events (MAKE), and steeper longitudinal decline in eGFR. The risks of kidney outcomes increased according to the severity of the acute infection (categorized by care setting into non-hospitalized, hospitalized, and admitted to intensive care). The findings provide insight into the long-term consequences of COVID-19 on kidney outcomes and suggest that post-acute COVID-19 care should include attention to kidney function and disease. Background: COVID-19 is associated with increased risk of post-acute sequelae involving pulmonary and extrapulmonary organ systems—referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. Methods: We built a cohort of 1,726,683 US Veterans identified from March 1, 2020 to March 15, 2021, including 89,216 patients who were 30-day survivors of COVID-19 and 1,637,467 non-infected controls. We examined risks of AKI, eGFR decline, ESKD, and major adverse kidney events (MAKE). MAKE was defined as eGFR decline ≥50%, ESKD, or all-cause mortality. We used inverse probability–weighted survival regression, adjusting for predefined demographic and health characteristics, and algorithmically selected high-dimensional covariates, including diagnoses, medications, and laboratory tests. Linear mixed models characterized intra-individual eGFR trajectory. Results: Beyond the acute illness, 30-day survivors of COVID-19 exhibited a higher risk of AKI (aHR, 1.94; 95% CI, 1.86 to 2.04), eGFR decline ≥30% (aHR, 1.25; 95% CI, 1.14 to 1.37), eGFR decline ≥40% (aHR, 1.44; 95% CI, 1.37 to 1.51), eGFR decline ≥50% (aHR, 1.62; 95% CI, 1.51 to 1.74), ESKD (aHR, 2.96; 95% CI, 2.49 to 3.51), and MAKE (aHR, 1.66; 95% CI, 1.58 to 1.74). Increase in risks of post-acute kidney outcomes was graded according to the severity of the acute infection (whether patients were non-hospitalized, hospitalized, or admitted to intensive care). Compared with non-infected controls, 30-day survivors of COVID-19 exhibited excess eGFR decline (95% CI) of −3.26 (−3.58 to −2.94), −5.20 (−6.24 to −4.16), and −7.69 (−8.27 to −7.12) ml/min per 1.73 m 2 per year, respectively, in non-hospitalized, hospitalized, and those admitted to intensive care during the acute phase of COVID-19 infection. Conclusions: Patients who survived COVID-19 exhibited increased risk of kidney outcomes in the post-acute phase of the disease. Post-acute COVID-19 care should include attention to kidney disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3697 · Cited by 6,758
Making Neighborhood-Disadvantage Metrics Accessible — The Neighborhood Atlas
Kind, A. J. H., & Buckingham, W. R. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1802313 · Cited by 3,310
Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation
Rubin, D. B. (2001) · Health Services and Outcomes Research Methodology · doi:10.1023/a:1020363010465 · Cited by 2,228 · cited 1×
“15 was taken as evidence of balance between the COVID-19 and VHA users group.(21,22) We estimated the excess burden per 1000 persons of the outcomes associated with COVID-19 at 6 months after T0, where excess burden was estimated by computing the difference between the average estimated survival probability from the w…”
MethodNegative Controls: A Tool for Detecting Confounding and Bias in Observational Studies
Lipsitch, M., Tchetgen Tchetgen, E., & Cohen, T. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181d61eeb · Cited by 1,583
High-dimensional characterization of post-acute sequelae of COVID-19
Al-Aly, Z., Xie, Y., & Bowe, B. (2021) · Nature · doi:10.1038/s41586-021-03553-9 · Cited by 1,518 · cited 4×
“Covariates Covariates included a set of 29 predefined potential confounders of the association between COVID-19 and adverse kidney outcomes.(1,2,15) Demographic, behavioral, and contextual characteristics included age, Area Deprivation Index, race, sex, and smoking status.”
BackgroundMethodInfluentialNeighborhood Socioeconomic Disadvantage and 30-Day Rehospitalization: A Retrospective Cohort Study
Kind, A. J. H., Jencks, S., Brock, J., Yu, M., Bartels, C., Ehlenbach, W., Greenberg, C., & Smith, M. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2946 · Cited by 1,379
Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128
Levey, A. S., & Stevens, L. A. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.02.337 · Cited by 1,005
Preoperative Renal Risk Stratification
Chertow, G. M., Lazarus, J. M., Christiansen, C. L., Cook, E. F., Hammermeister, K. E., Grover, F., & Daley, J. (1997) · Circulation · doi:10.1161/01.cir.95.4.878 · Cited by 801
COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets
Delorey, T. M., Ziegler, C. G. K., Heimberg, G., Normand, R., Yang, Y., Segerstolpe, Å., Abbondanza, D., Fleming, S. J., Subramanian, A., Montoro, D. T., et al. (2021) · Nature · doi:10.1038/s41586-021-03570-8 · Cited by 794
Cited by
Long COVID: major findings, mechanisms and recommendations
Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00846-2 · Cited by 4,153
Long-term cardiovascular outcomes of COVID-19
Xie, Y., Xu, E., Bowe, B., & Al-Aly, Z. (2022) · Nature Medicine · doi:10.1038/s41591-022-01689-3 · Cited by 2,029
Self-citationLong COVID after breakthrough SARS-CoV-2 infection
Al-Aly, Z., Bowe, B., & Xie, Y. (2022) · Nature Medicine · doi:10.1038/s41591-022-01840-0 · Cited by 866
Self-citationAcute and postacute sequelae associated with SARS-CoV-2 reinfection
Bowe, B., Xie, Y., & Al-Aly, Z. (2022) · Nature Medicine · doi:10.1038/s41591-022-02051-3 · Cited by 639
Self-citationLong COVID science, research and policy
Al-Aly, Z., Davis, H., McCorkell, L., Soares, L., Wulf-Hanson, S., Iwasaki, A., & Topol, E. J. (2024) · Nature Medicine · doi:10.1038/s41591-024-03173-6 · Cited by 538
Self-citation
Metadata
- Authors
- Bowe, B., Xie, Y., Xu, E., & Al-Aly, Z.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2021-11
- Volume
- 32
- Issue
- 11
- Pages
- 2851-2862
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W3196529166
- Cited by
- 333
- References
- 31
- FWCI
- 26.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kidney Outcomes in Long COVID. https://app.cochat.ai/papers/10.1681/asn.2021060734
- The paper
- Bowe, B., Xie, Y., Xu, E., & Al-Aly, Z. (2021). Kidney Outcomes in Long COVID. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2021060734
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.